CYNTHIA RIZZARDI: Open Payments
NPI 1386945772 · TRUMBULL, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$786 in 31 payments from 10 companies in 2025. Trend: 2023 $791 · 2024 $541 · 2025 $786
Food & beverage: $736Long term medical supply or device loan: $50
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | $433 |
| Lilly USA, LLC | 5 | $94 |
| Xeris Pharmaceuticals, Inc. | 2 | $52 |
| Abbott Laboratories | 1 | $50 |
| CeQur Corporation | 1 | $41 |
| Insulet Corporation | 2 | $31 |
| Mannkind Corporation | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Amgen Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
Products named: JARDIANCE, MOUNJARO, FREESTYLE INSULINX, CeQur Simplicity, Omnipod, GVOKE HYPOPEN, AFREZZA, REZDIFFRA.
Industry payments across CT — which companies pay providers there.
